Syndax stops pivotal cancer trial early for efficacy but details disappoint, sending stock down

Syndax Pharmaceuticals has stopped a pivotal cancer clinical trial early for efficacy—which sent the biotech's share price down 9%. The negative reaction to superficially positive news reflects the failure to live up to efficacy expectations and the emergence of a safety concern.